<DOC>
	<DOCNO>NCT02185963</DOCNO>
	<brief_summary>The patient achieve LDL-C level currently recommend target may still experience cardiovascular event . To reduce risk coronary heart disease ( CHD ) , raise HDL-C lower TG may secondary therapeutic target . However , increase HDL-C level mean increase functional HDL-C . It also remain controversial whether functional HDL important total circulating level HDL-C reduce CHD . Actually , increased concentration HDL alone might ineffective indicate qualitative change HDL level response drug intervention require result clinical benefit . The investigator set clinical trial investigate effect ( rosuva ) statin treatment functional HDL-C level particularly Asian population , relatively low HDL-C .</brief_summary>
	<brief_title>Effect Rosuvastatin Function High Density Lipoprotein Cholesterol Type 2 Diabetes</brief_title>
	<detailed_description>1 . Study design Study subject Number Subjects ( N = 30 ) 2 . Study outcome Primary outcome - functional HDL-C Secondary outcome - Non-HDL cholesterol 3 . Evaluation functional aspect HDL Cholesterol efflux macrophage LDL-induced monocyte chemotactic activity ( MCA ) Assay Quantitation gene expression monocyte chemotactic protein-1 ( MCP-1 )</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>1 . Type 2 diabetes 2 . HbA1c ≥ 7.5 % 3 . Age ≥ 30 4. low HDLC ( &lt; 40 mg/dl men &lt; 50 mg/dl woman ) 1 risk factor : 1 ) Body mass index ( BMI ) ≥ 25 kg/m2 ( overweight ) ; 2 ) LDLC level ≥ 130 mg/dl ; 3 ) TG level ≥150 mg/dl ; 4 ) Systolic blood pressure ( SBP ) /diastolic blood pressure ( DBP ) ≥140/90 mmHg take antihypertensive medication ; 5 ) Current smoker ; 6 ) Family history CHD . 1 . Contraindication rosuvastatin 2 . Pregnant breast feed woman 3 . Reproductiveage woman refuse contraception 4 . Type 1 diabetes , gestational diabetes , diabetes secondary cause 5 . Chronic hepatitis B C ( except healthy carrier HBV ) , liver disease ( AST/ALT &gt; 3fold upper limit normal ) 6 . Renal failure ( Cr &gt; 2.0 ) 7 . Cancer within 5 year ( except squamous cell cancer , cervical cancer , thyroid cancer appropriate treatment ) 8 . Not appropriate lipid lower treatment 9 . Medications affect glycemic control 10 . Diseases affect efficacy safety statin 11 . Other clinical trial within 30 day</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>HDL function</keyword>
	<keyword>Cholesterol efflux</keyword>
	<keyword>MCA assay</keyword>
	<keyword>MCP-1</keyword>
</DOC>